. 2014 Mar 20;8(2):198–215. doi: 10.1007/s12072-014-9523-y

Table 4.

Summary of secondary endpoints including complication incidences related to steroid usage in this study

First author	Year	Study center	Group	No. of patients (n)	HCV recurrence (n)	HCC recurrence (n)	Diabetes (n)	Hypertension (n)	Kidney dysfunction (n)	Bacterial infection (n)	CMV (n)
Comparison of Tac-based regimen with induction agents or not (Sect. I)
Langrehr [25]	2002	University of Berlin, Germany	Tac + steroid	15	3					2
Langrehr [25]	2002	University of Berlin, Germany	Tac + MMF	15	2					0
Pelletier [26]	2005	University of Michigan, Ann Arbor, USA	Tac + MMF + steroid	36	17					10
Pelletier [26]	2005	University of Michigan, Ann Arbor, USA	Tac + MMF	36	18					19
Margarit [27]	2005	Universidad Autònoma Barcelona, Spain	Tac + steroid	32	20	0	6	3	17	30	3
Margarit [27]	2005	Universidad Autònoma Barcelona, Spain	Tac	28	11	1	2	1	20	26	0
Reggiani [17]	2005	Instituto di Ricovero e Cura a Caraterre Scientifico (IRCCS) Policlinico San Matteo, Italy	Tac + MMF + steroid	18			5	5	3	5
Reggiani [17]	2005		Tac + MMF	12			2	2	2	6
Junge [28]	2005	Charité Berlin Campus Virchow Klinikum, Germany	Tac + steroid	14			6
Junge [28]	2005	Charité Berlin Campus Virchow Klinikum, Germany	Tac + MMF	16			2
Chen [9]	2007	Tongji Medical College, China	Tac + MMF + steroid	26		18
Chen [9]	2007	Tongji Medical College, China	Tac + MMF	28		11
Vivarelli et al. [29]	2007	University of Bologna, Italy	Tac + steroid	16	15		7
Vivarelli et al. [29]	2007	University of Bologna, Italy	Tac	23	22		7
Manousou [30]	2009	University College London, UK	Azathioprine + steroid + Tac	49	10		14		19		10
Manousou [30]	2009	University College London, UK	Tac	54	17		15		20		7
Weiler [31]	2010	Hospital of Johannes Gutenberg University Mainz, Germany	Tac + steroid	54	6		12	31
Weiler [31]	2010	Hospital of Johannes Gutenberg University Mainz, Germany	Tac	56	10		18	36
Comparison of Tac-based regimen with induction agents or not (Sect. II)
Eason [32]	2003	Ochsner Clinic Foundation, USA	Tac + MMF + steroid	59	24		8			13	14
Eason [32]	2003	Ochsner Clinic Foundation, USA	RATG + Tac + MMF	60	18		1			15	3
Boillot [33]	2005	Hospital Edouard Herriot, France	Tac + steroid	347			53	50	82	39	40
Boillot [33]	2005	Hospital Edouard Herriot, France	Daclizumab + Tac	351			20	45	98	39	18
Spada [34]	2006	University of Pittsburgh Medical Center, Italy	Tac + steroid	36	8			8	1	30
Spada [34]	2006	University of Pittsburgh Medical Center, Italy	Basiliximab + Tac	36	7			3	4	14
Humar [35]	2007	University of Minnesota Minneapolis, USA	Tac + MMF + steroid	83	46		27				1
Humar [35]	2007	University of Minnesota Minneapolis, USA	Basiliximab + Tac + MMF	83	32		10				1
Kato [36]	2007	University of Miami School of Medicine, USA	Tac/MMF + steroid	39	6		14	17		12
Kato [36]	2007	University of Miami School of Medicine, USA	Daclizumab + Tac/MMF	31	4		3	10		2
Gras [37]	2008	Luc University Clinics, Université Catholique de Louvain, Belgium	Tac + steroid	34						34
Gras [37]	2008		Basiliximab + Tac	50						50
Foroncewicz [18]	2009	Medical University of Warsaw, Poland	Tac + steroid	18			4			10
Foroncewicz [18]	2009	Medical University of Warsaw, Poland	Daclizumab + Tac	7			1			3
Klintmalm [38]	2011	Baylor University Medical Center, USA	Tac + MMF + steroid	72	55		24	51
Klintmalm [38]	2011	Baylor University Medical Center, USA	Daclizumab + Tac + MMF	146	99		27	97

CMV cytomegalovirus, HBV hepatitis B virus, HCV hepatitis C virus, HCC hepatocellular carcinoma, MMF mycophenolate mofetil, RATG rabbit antithymocyte globulin, Tac tacrolimus